These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 23044174)

  • 1. Experience gathered from retrospective series on renal cell carcinoma is useful, but now it is time for a global claim for academically driven prospective studies.
    Porta C; Paglino C
    Eur Urol; 2013 Jul; 64(1):71-2. PubMed ID: 23044174
    [No Abstract]   [Full Text] [Related]  

  • 2. Reply from authors re: Camillo Porta, Chiara Paglino. Experience gathered from retrospective series on renal cell carcinoma is useful, but now it is time for a global claim for academically driven prospective studies. Eur Urol 2013;64:71-2: are retrospective data of any value to the specialist treating renal cell carcinoma?
    Weikert S; Grünwald V
    Eur Urol; 2013 Jul; 64(1):72-3. PubMed ID: 23092545
    [No Abstract]   [Full Text] [Related]  

  • 3. Retrospective comparison of triple-sequence therapies in metastatic renal cell carcinoma.
    Busch J; Seidel C; Erber B; Issever AS; Hinz S; Kempkensteffen C; Magheli A; Miller K; Grünwald V; Weikert S
    Eur Urol; 2013 Jul; 64(1):62-70. PubMed ID: 22999519
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Maturing of renal cancer therapeutics.
    Stadler WM
    J Clin Oncol; 2014 Mar; 32(8):722-4. PubMed ID: 24516015
    [No Abstract]   [Full Text] [Related]  

  • 5. Improving outcomes in patients with advanced renal cell carcinoma.
    Sosman JA
    Expert Rev Anticancer Ther; 2008 Mar; 8(3):481-90. PubMed ID: 18366295
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combination therapy in metastatic renal cell cancer.
    Ravaud A; Gross-Goupil M; Bellmunt J
    Semin Oncol; 2013 Aug; 40(4):472-81. PubMed ID: 23972711
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Durable remission of metastatic renal cell carcinoma with gemcitabine and capecitabine after failure of targeted therapy.
    Richey SL; Ng C; Lim ZD; Jonasch E; Tannir NM
    J Clin Oncol; 2011 Mar; 29(8):e203-5. PubMed ID: 21172884
    [No Abstract]   [Full Text] [Related]  

  • 8. Effects of antiangiogenic therapy.
    von Falck C; Wacker F; Rosenthal H
    J Vasc Interv Radiol; 2012 Nov; 23(11):1503. PubMed ID: 23101922
    [No Abstract]   [Full Text] [Related]  

  • 9. [New treatment of metastatic renal cancer. The Danish Society of Clinical Oncology].
    Sengeløv L; Geertsen PF;
    Ugeskr Laeger; 2007 Mar; 169(12):1117. PubMed ID: 17394828
    [No Abstract]   [Full Text] [Related]  

  • 10. Efficacy of Second-line Targeted Therapy for Renal Cell Carcinoma According to Change from Baseline in International Metastatic Renal Cell Carcinoma Database Consortium Prognostic Category.
    Davis ID; Xie W; Pezaro C; Donskov F; Wells JC; Agarwal N; Srinivas S; Yuasa T; Beuselinck B; Wood LA; Ernst DS; Kanesvaran R; Knox JJ; Pantuck A; Saleem S; Alva A; Rini BI; Lee JL; Choueiri TK; Heng DYC
    Eur Urol; 2017 Jun; 71(6):970-978. PubMed ID: 27771126
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Does axitinib (AG-01376) have a future role in metastatic renal cell carcinoma and other malignancies?
    Goldstein R; Pickering L; Larkin J
    Expert Rev Anticancer Ther; 2010 Oct; 10(10):1545-57. PubMed ID: 20942625
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sorafenib for the treatment of renal cancer.
    Strumberg D
    Expert Opin Pharmacother; 2012 Feb; 13(3):407-19. PubMed ID: 22263843
    [TBL] [Abstract][Full Text] [Related]  

  • 13. How to interpret phase II data for everolimus plus bevacizumab in renal cell carcinoma.
    Escudier B
    J Clin Oncol; 2010 May; 28(13):2125-6. PubMed ID: 20368540
    [No Abstract]   [Full Text] [Related]  

  • 14. Activity of single-agent bevacizumab in patients with metastatic renal cell carcinoma previously treated with vascular endothelial growth factor tyrosine kinase inhibitors.
    Turnbull JD; Cobert J; Jaffe T; Harrison MR; George DJ; Armstrong AJ
    Clin Genitourin Cancer; 2013 Mar; 11(1):45-50. PubMed ID: 23041453
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Entropy increases in kidney cancer treatment, but a bit of simplicity may emerge from chaos.
    Porta C
    Eur Urol; 2011 Dec; 60(6):1171-2. PubMed ID: 21820238
    [No Abstract]   [Full Text] [Related]  

  • 16. Treatment selection for first-line metastatic renal cell carcinoma in Australia: Impact of new therapy options.
    Schmidt A; Azad A; Goh J; Harris C; Joshua AM; Weickhardt A; Krieger L
    Asia Pac J Clin Oncol; 2019 Nov; 15 Suppl 10():3-10. PubMed ID: 31762165
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combination of cabozantinib and immune checkpoint inhibitors in advanced renal cell carcinoma: update from the European Society for Medical Oncology 2020.
    Sarkis J; Khalil N; Alkassis M
    Future Oncol; 2021 Mar; 17(9):991-992. PubMed ID: 33533650
    [No Abstract]   [Full Text] [Related]  

  • 18. Evolving role of novel targeted agents in renal cell carcinoma.
    Hutson TE; Figlin RA
    Oncology (Williston Park); 2007 Sep; 21(10):1175-80; discussion 1184, 1187, 1190. PubMed ID: 17926797
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sunitinib, pazopanib or sorafenib for the treatment of patients with late relapsing metastatic renal cell carcinoma.
    Santoni M; Conti A; Porta C; Procopio G; Sternberg CN; Basso U; De Giorgi U; Bracarda S; Rizzo M; Ortega C; Massari F; Iacovelli R; Derosa L; Masini C; Milella M; Di Lorenzo G; Atzori F; Pagano M; Buti S; De Vivo R; Mosca A; Rossi M; Paglino C; Verzoni E; Cerbone L; Muzzonigro G; Falconi M; Montironi R; Burattini L; Santini D; Cascinu S
    J Urol; 2015 Jan; 193(1):41-7. PubMed ID: 25046616
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeted therapies: treating advanced kidney cancer-miles to go before we sleep.
    Linehan WM; Srinivasan R
    Nat Rev Clin Oncol; 2013 Nov; 10(11):614-5. PubMed ID: 24129349
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.